New drug combo aims for deep remission in blood cancer patients
NCT ID NCT03477539
Summary
This study tested whether adding the drug daratumumab before and after a stem cell transplant could help patients with multiple myeloma achieve deeper remission. The trial involved 49 patients eligible for transplant and measured whether cancer cells became undetectable after treatment. Researchers tracked how long patients remained cancer-free and monitored side effects of this combined approach.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLASMA CELL MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980, United States
Conditions
Explore the condition pages connected to this study.